However, despite these treatment advances, most of HER2-positive breast cancer would eventually progress due to intrinsic and acquired HER2 agent resistance, highlighting the need to develop novel agents and combination strategies to overcome resistance. Here, ERBB2 is linked to breast carcinoma.